After reformulated formulations of epoetin-α were used subcutaneously outside of the United States, a rise in cases of rHuEPO-associated PRCA occurred in the mid-1990s until 2004-2005 [16]. The gene discussed is EPO; the disease is pure red-cell aplasia.